Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prolonged Episodes of Paroxysmal Exertion-Induced Dystonia in Glut1 Deficiency Syndrome.

Neuropediatrics·2026
Same author

"Not always the magic bullet"-Insufficient seizure control by ketogenic dietary therapies in Glut1 Deficiency Syndrome.

Epilepsia open·2026
Same author

The genotypic and phenotypic landscape of PDHA1-related pyruvate dehydrogenase complex deficiency.

Brain : a journal of neurology·2025
Same author

Toward a working definition of ketogenic diet resistance in GLUT1 deficiency syndrome.

Epileptic disorders : international epilepsy journal with videotape·2025
Same author

Exploring ketogenic diet resistance in glucose transporter type 1 deficiency syndrome: A comprehensive review and critical appraisal.

Epilepsia open·2024
Same author

Distinct neurodevelopmental and epileptic phenotypes associated with gain- and loss-of-function GABRB2 variants.

EBioMedicine·2024

Related Experiment Video

Updated: Jul 12, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

GLUT1 deficiency syndrome--2007 update.

Joerg Klepper1, Baerbel Leiendecker

  • 1Children's Hospital, Aschaffenburg, Germany. joerg.klepper@klinikum-aschaffenburg.de

Developmental Medicine and Child Neurology
|August 28, 2007
PubMed
Summary

Glucose transporter type 1 deficiency syndrome (GLUT1DS) causes drug-resistant epilepsy and developmental issues due to impaired brain glucose uptake. A ketogenic diet is the primary treatment, improving seizures but with less impact on neurodevelopment.

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Related Experiment Videos

Last Updated: Jul 12, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Area of Science:

  • Neurology
  • Genetics
  • Biochemistry

Background:

  • Glucose transporter type 1 deficiency syndrome (GLUT1DS) is an epileptic encephalopathy characterized by impaired glucose transport into the brain.
  • Key biochemical findings include low cerebrospinal fluid (CSF) glucose (hypoglycorrhachia) with normal CSF lactate in the presence of normal blood glucose.
  • Clinical manifestations include early-onset, drug-resistant epilepsy, developmental delay, and movement disorders.

Purpose of the Study:

  • To review the current understanding of GLUT1 deficiency syndrome, encompassing its clinical, biochemical, and genetic aspects.
  • To highlight recent advances in disease mechanisms, treatment strategies, and the impact of the ketogenic diet.
  • To summarize data from 84 published cases to provide insights into this rare disorder.

Main Methods:

  • Literature review of published cases and recent research on GLUT1DS.
  • Analysis of clinical, biochemical, and genetic data from 84 patients.
  • Synthesis of information regarding disease manifestations, genotype-phenotype correlations, and treatment outcomes.

Main Results:

  • Most patients have de novo heterozygous mutations in the GLUT1 gene.
  • The ketogenic diet is effective in controlling seizures by providing an alternative brain fuel source.
  • While seizures improve, the impact of the ketogenic diet on neurodevelopmental outcomes is less pronounced.

Conclusions:

  • GLUT1DS is a treatable condition, with early introduction of the ketogenic diet being crucial.
  • Further research is needed to fully understand genotype-phenotype correlations and optimize neurodevelopmental outcomes.
  • Advances in molecular analysis, biochemical studies, and animal models are enhancing our comprehension of GLUT1DS.